09/ 939,883

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN
NEWS 26	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 27	MAR 29	WPIFV now available on STN
NEWS 28	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 29	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:43:35 ON 09 APR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:43:43 ON 09 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 APR 2004 HIGHEST RN 672883-15-7
DICTIONARY FILE UPDATES: 7 APR 2004 HIGHEST RN 672883-15-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\09939883.str



chain nodes :
22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
ring/chain nodes :
16 17 24
chain bonds :

7-11
ring/chain bonds :
14-16 15-17
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 11-12 11-15 12-13 13-14
14-15
exact/norm bonds :
7-11 14-16 15-17
exact bonds :
11-12 11-15 12-13 13-14 14-15
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
isolated ring systems :
containing 1 :

G1:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 22:Atom 23:CLASS 24:CLASS
25:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 08:44:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6616 TO ITERATE

100.0% PROCESSED 6616 ITERATIONS 137 ANSWERS
SEARCH TIME: 00.00.01

L2 137 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 08:44:10 ON 09 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 Apr 2004 VOL 140 ISS 16
FILE LAST UPDATED: 8 Apr 2004 (20040408/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 3 L2

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:633280 CAPLUS
DOCUMENT NUMBER: 139:179984
TITLE: Preparation of quinoline derivatives as neuropeptide inhibitors
INVENTOR(S): Mattei, Patrizio; Mueller, Werner; Neidhart, Werner; Nettekoven, Matthias Heinrich; Pflieger, Philippe
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Switz.
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003153553	A1	20030814	US 2003-358006	20030204
US 6696467	B2	20040224		
WO 2003066055	A1	20030814	WO 2003-EP777	20030127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: EP 2002-1967 A 20020204
OTHER SOURCE(S): MARPAT 139:179984
GI



I

AB Compds. of general formula (I) as well as pharmaceutically acceptable salts and esters thereof [R1, R2 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl, hydroxyalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylalkylcarbonyl, carbocyclyl, carbocyclylalkyl, amino, alkyl-SO2-, aryl-SO2-, heterocyclyl-SO2-, SO2NH2; or R1 and R2 together with the N atom to which they are attached form a 5- to 10-membered heterocyclic ring which optionally comprises a second heteroatom selected from nitrogen or oxygen and wherein the heterocyclyc ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl and alkoxy; R3 = H, alkyl, NH2, halo; R4 = H, halogen, heterocyclyl, NH2, alkyl; A = a 5 to 7-membered saturated heterocyclic ring comprising the nitrogen atom which is attached to the quinoline ring and optionally a second heteroatom which is selected from oxygen, sulfur or nitrogen and, wherein the ring A is optionally substituted by one to three substituents independently selected from the group consisting of alkyl, alkoxy, hydroxy, amino, acetylamino, cyano, hydroxyalkyl, alkoxyalkyl, cycloalkylalkoxy, and cycloalkylalkoxyalkyl] are prepared These compds. are potent inhibitors of neuropeptide Y and can be used in the form of pharmaceutical prepns. to reduce appetite for the treatment or prevention of various disease states and related morbidities including obesity. Thus, a suspension of 1.01 g (3 mmol) 7-iodo-2-methyl-4-pyrrolidin-1-ylquinoline, 0.186 g (0.3 mmol) racemic BINAP, 33.7 mg (0.15 mmol) palladium(II) acetate, and 0.87 g (9 mmol) sodium tert-butylate in toluene (25 mL) was treated at room temperature with 0.427 g (6 mmol) aminomethylcyclopropane and then heated to reflux under an argon atmospheric for 20 h to give, after workup and silica gel chromatog., 253 mg (30%) cyclopropylmethyl(2- methyl-4-pyrrolidin-1-ylquinolin-7-yl)amine as light yellow foam. Isobutyl(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)amine and furan-2-carboxylic acid (2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)amide showed IC50 of 0.7 and 0.3 nM, resp., for inhibiting the binding of [125I]peptide YY to recombinant mouse NPY5-receptor expressed in human embryonic kidney 293 cells (HEK293).

IT **581066-78-6P**, 2-Methyl-7-nitro-4,6-di(pyrrolidin-1-yl)quinoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinoline derivs. as neuropeptide inhibitors to reduce appetite for treatment or prevention of obesity)

RN 581066-78-6 CAPLUS
CN Quinoline, 2-methyl-7-nitro-4,6-di-1-pyrrolidinyl- (9CI) (CA INDEX NAME)



IT **581066-10-6P**, 2-Methyl-7-(piperidin-1-yl)-4-(pyrrolidin-1-yl)quinoline **581066-11-7P**, 2-Methyl-4,7-di(pyrrolidin-1-yl)quinoline **581066-12-8P**, 2-Methyl-7-(morpholin-4-yl)-4-(pyrrolidin-1-yl)quinoline **581066-13-9P**, 7-(Azepan-1-yl)-2-methyl-4-(pyrrolidin-1-yl)quinoline **581066-51-5P**, 7-(3,4-Dihydro-1H-isoquinolin-2-yl)-2-methyl-4-(pyrrolidin-1-yl)quinoline **581066-77-5P**, N-[2-Methyl-4,6-di(pyrrolidin-1-yl)quinolin-7-yl]acetamide hydrochloride **581066-79-7P**, [2-Methyl-4,6-di(pyrrolidin-1-yl)quinolin-7-yl]amine hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline derivs. as neuropeptide inhibitors to reduce appetite for treatment or prevention of obesity)

RN 581066-10-6 CAPLUS
CN Quinoline, 2-methyl-7-(1-piperidinyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 581066-11-7 CAPLUS
CN Quinoline, 2-methyl-4,7-di-1-pyrrolidinyl- (9CI) (CA INDEX NAME)



RN 581066-12-8 CAPLUS
CN Quinoline, 2-methyl-7-(4-morpholinyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 581066-13-9 CAPLUS
CN Quinoline, 7-(hexahydro-1H-azepin-1-yl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 581066-51-5 CAPLUS
CN Quinoline, 7-(3,4-dihydro-2(1H)-isoquinolinyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 581066-77-5 CAPLUS
CN Acetamide, N-(2-methyl-4,6-di-1-pyrrolidinyl-7-quinolinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

09/ 939,883

RN 581066-79-7 CAPLUS
CN 7-Quinolinamine, 2-methyl-4,6-di-1-pyrrolidinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:185085 CAPLUS
DOCUMENT NUMBER: 136:247596
TITLE: Preparation of 7-aryl-4-(1-azacycloalkyl)quin(az)olines and analogs as NPY receptor antagonists
INVENTOR(S): Breu, Volker; Dautzenberg, Frank; Guerry, Philippe; Nettekoven, Matthias Heinrich; Pflieger, Philippe
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020488	A2	20020314	WO 2001-EP10014	20010830
WO 2002020488	A3	20020516		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002052356	A1	20020502	US 2001-939883	20010827
AU 2002010474	A5	20020322	AU 2002-10474	20010830
BR 2001013710	A	20030603	BR 2001-13710	20010830
EP 1318981	A2	20030618	EP 2001-978324	20010830
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004508357	T2	20040318	JP 2002-525110	20010830

PRIORITY APPLN. INFO.: EP 2000-119262 A 20000906
WO 2001-EP10014 W 20010830

OTHER SOURCE(S): MARPAT 136:247596
GI



I

AB Title compds. [I; R1 = (cyclo)alkyl, CF3, aralkyl; R2 = H, halo, alkyl, alkoxy, etc.; R3 = (hetero)aryl; NR4R5 = (un)substituted heterocyclyl; Z1 = CH or N] were prepared Thus, 4-chloro-7-iodo-2-methylquinoline was aminated by pyrrolidine and the product arylated by 3-ClC6H4B(OH)2 to give I [R1 = Me, R2 = H, R3 = 7-(3-chlorophenyl), R4R5 = (CH2)4, Z1 = CH]. Data for biol. activity of I were given.

IT **403849-18-3P 403849-19-4P 403849-20-7P**
403849-21-8P 403849-22-9P 403849-23-0P
403849-24-1P 403849-25-2P 403849-26-3P
403849-27-4P 403849-28-5P 403849-29-6P
403849-30-9P 403849-31-0P 403849-32-1P
403849-33-2P 403849-34-3P 403849-35-4P
403849-43-4P 403849-44-5P 403849-45-6P
403849-46-7P 403849-48-9P 403849-49-0P
403849-90-1P 403849-92-3P 403849-96-7P
403849-98-9P 403850-00-0P 403850-02-2P
403850-04-4P 403850-06-6P 403850-08-8P
403850-10-2P 403850-12-4P 403850-14-6P
403850-16-8P 403850-17-9P 403850-18-0P
403850-19-1P 403850-20-4P 403850-22-6P
403850-23-7P 403850-25-9P 403850-27-1P
403850-29-3P 403850-31-7P 403850-32-8P
403850-33-9P 403850-35-1P 403850-37-3P
403850-39-5P 403850-40-8P 403850-41-9P
403850-43-1P 403850-45-3P 403850-47-5P
403850-50-0P 403850-52-2P 403850-54-4P
403850-56-6P 403850-58-8P 403850-60-2P
403850-62-4P 403850-64-6P 403850-65-7P
403853-09-8P 403853-11-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 7-aryl-4-(1-azacycloalkyl)quin(az)olines and analogs as NPY receptor antagonists)

RN 403849-18-3 CAPLUS

CN Quinoline, 7-(3-chlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-19-4 CAPLUS

CN Quinoline, 2-methyl-4-(1-pyrrolidinyl)-7-[3-(trifluoromethyl)phenyl]-

(9CI) (CA INDEX NAME)



RN 403849-20-7 CAPLUS
CN Benzenamine, 3-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]- (9CI) (CA INDEX NAME)



RN 403849-21-8 CAPLUS
CN Ethanone, 1-[4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 403849-22-9 CAPLUS
CN Quinoline, 2-methyl-7-phenyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-23-0 CAPLUS
CN Quinoline, 7-(4-methoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-24-1 CAPLUS
CN Quinoline, 2-methyl-4-(1-pyrrolidinyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 403849-25-2 CAPLUS
CN Quinoline, 2-methyl-7-(3-pyridinyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-26-3 CAPLUS
CN Quinoline, 2-methyl-7-(5-pyrimidinyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-27-4 CAPLUS
CN Quinoline, 2-methyl-4-(1-piperidinyl)-7-[3-(trifluoromethyl)phenyl]- (9CI)

(CA INDEX NAME)



RN 403849-28-5 CAPLUS
CN Quinoline, 7-(3-chlorophenyl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-29-6 CAPLUS
CN Ethanone, 1-[4-[2-methyl-4-(1-piperidinyl)-7-quinolinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 403849-30-9 CAPLUS
CN Benzenamine, 3-[2-methyl-4-(1-piperidinyl)-7-quinolinyl]- (9CI) (CA INDEX NAME)



RN 403849-31-0 CAPLUS
CN Quinoline, 7-(4-methoxyphenyl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-32-1 CAPLUS
CN Quinoline, 2-methyl-4-(1-piperidinyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 403849-33-2 CAPLUS
CN Quinoline, 2-methyl-7-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-34-3 CAPLUS
CN Quinoline, 7-(1H-indol-5-yl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-35-4 CAPLUS
CN Quinoline, 2-methyl-4-(1-piperidinyl)-7-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 403849-43-4 CAPLUS
CN Quinoline, 4-(3,4-dihydro-2(1H)-isoquinolinyl)-2-methyl-7-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 403849-44-5 CAPLUS
CN Quinoline, 5-(3-chlorophenyl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-45-6 CAPLUS

CN Quinoline, 2-methyl-4-(1-piperidinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 403849-46-7 CAPLUS
CN Quinoline, 5-(3-chlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-48-9 CAPLUS
CN Quinoline, 4-(hexahydro-1H-azepin-1-yl)-2-methyl-7-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 403849-49-0 CAPLUS
CN Quinoline, 6-(3-chlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-90-1 CAPLUS
CN Formic acid, compd. with 7-(4-ethylphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403849-89-8
CMF C22 H24 N2



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403849-92-3 CAPLUS
CN Formic acid, compd. with 7-(3,4-dimethoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403849-91-2
CMF C22 H24 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403849-96-7 CAPLUS
CN Formic acid, compd. with 7-(2,6-difluorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403849-95-6
CMF C20 H18 F2 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403849-98-9 CAPLUS
CN Formic acid, compd. with 7-(2,4-dimethoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403849-97-8

CMF C22 H24 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH—OH

RN 403850-00-0 CAPLUS
CN Formic acid, compd. with 2-methyl-4-(1-pyrrolidinyl)-7-[4-(trifluoromethyl)phenyl]quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403849-99-0
CMF C21 H19 F3 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH—OH

RN 403850-02-2 CAPLUS
CN Formic acid, compd. with 2-methyl-7-[4-(methylthio)phenyl]-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-01-1
CMF C21 H22 N2 S



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-04-4 CAPLUS
CN Formic acid, compd. with 7-(2-methoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-03-3
CMF C21 H22 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-06-6 CAPLUS
CN Formic acid, compd. with 7-(3-ethoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-05-5
CMF C22 H24 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-08-8 CAPLUS
CN Formic acid, compd. with N-[3-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-07-7
CMF C22 H23 N3 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-10-2 CAPLUS
CN Formic acid, compd. with 2-methyl-4-(1-pyrrolidinyl)-7-[4-(trifluoromethoxy)phenyl]quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-09-9
CMF C21 H19 F3 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-12-4 CAPLUS
CN Formic acid, compd. with 7-(1,3-benzodioxol-5-yl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-11-3
CMF C21 H20 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-14-6 CAPLUS
CN Formic acid, compd. with 7-(2-benzofuranyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-13-5
CMF C22 H20 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-16-8 CAPLUS
CN Formic acid, compd. with 7-benzo[b]thien-2-yl-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-15-7
CMF C22 H20 N2 S



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-17-9 CAPLUS
CN Quinoline, 7-(3-chloro-4-fluorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403850-18-0 CAPLUS
CN Formic acid, compd. with 7-(3-chloro-4-fluorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-17-9
CMF C20 H18 Cl F N2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-19-1 CAPLUS
CN Ethanone, 1-[5-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 403850-20-4 CAPLUS

CN Formic acid, compd. with 1-[5-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]-2-thienyl]ethanone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-19-1
CMF C20 H20 N2 O S



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-22-6 CAPLUS
CN Quinoline, 7-(3,4-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403850-23-7 CAPLUS
CN Formic acid, compd. with 7-(3,4-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-22-6
CMF C20 H18 Cl2 N2



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-25-9 CAPLUS
CN Formic acid, compd. with 7-(2-fluorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-24-8
CMF C20 H19 F N2



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-27-1 CAPLUS
CN Formic acid, compd. with 2-methyl-7-(1-naphthalenyl)-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-26-0

09/ 939,883

CMF C24 H22 N2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-29-3 CAPLUS
CN Formic acid, compd. with 7-(2-chlorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-28-2
CMF C20 H19 Cl N2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-31-7 CAPLUS
CN Formic acid, compd. with 7-(4-ethenylphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-30-6
CMF C22 H22 N2



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-32-8 CAPLUS
CN Quinoline, 7-(3,5-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403850-33-9 CAPLUS
CN Formic acid, compd. with 7-(3,5-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-32-8
CMF C20 H18 Cl2 N2



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-35-1 CAPLUS
CN Formic acid, compd. with 7-(3-methoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-34-0
CMF C21 H22 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-37-3 CAPLUS
CN Benzoic acid, 3-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]-, ethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 403850-36-2
CMF C23 H24 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-39-5 CAPLUS
CN Benzoic acid, 4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]-, ethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 403850-38-4
CMF C23 H24 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-40-8 CAPLUS
CN Phenol, 2-methoxy-4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]- (9CI) (CA INDEX NAME)



RN 403850-41-9 CAPLUS
CN Formic acid, compd. with 2-methoxy-4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-40-8
CMF C21 H22 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-43-1 CAPLUS
CN Formic acid, compd. with N-[4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-42-0
CMF C22 H23 N3 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-45-3 CAPLUS
CN Formic acid, compd. with N,N-dimethyl-4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]benzenamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-44-2
CMF C22 H25 N3



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-47-5 CAPLUS
CN Formic acid, compd. with N-methyl-4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-46-4
CMF C22 H23 N3 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-50-0 CAPLUS
CN Formic acid, compd. with 3-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-49-7
CMF C20 H20 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-52-2 CAPLUS
CN Formic acid, compd. with 2-methoxy-5-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-51-1

09/ 939,883

CMF C21 H22 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-54-4 CAPLUS
CN Formic acid, compd. with 7-(2,6-dimethoxy-3-pyridinyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-53-3
CMF C21 H23 N3 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-56-6 CAPLUS
CN Formic acid, compd. with 2-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-55-5
CMF C20 H20 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-58-8 CAPLUS
CN Formic acid, compd. with 2-methyl-7-(4-phenoxyphenyl)-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-57-7
CMF C26 H24 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-60-2 CAPLUS
CN Formic acid, compd. with 7-(2,6-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

09/ 939,883

CM 1

CRN 403850-59-9
CMF C20 H18 Cl2 N2



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-62-4 CAPLUS
CN Formic acid, compd. with 2-methyl-4-(1-pyrrolidinyl)-7-[3-(trifluoromethoxy)phenyl]quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-61-3
CMF C21 H19 F3 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-64-6 CAPLUS
CN Formic acid, compd. with 2-methyl-4-(1-pyrrolidinyl)-7-[2-(trifluoromethoxy)phenyl]quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-63-5
CMF C21 H19 F3 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-65-7 CAPLUS
CN Quinoline, 2-methyl-7-(2-naphthalenyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403853-09-8 CAPLUS
CN Formic acid, compd. with 2-methyl-7-(2-naphthalenyl)-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-65-7
CMF C24 H22 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 403853-11-2 CAPLUS
CN Formic acid, compd. with 7-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403853-10-1
CMF C22 H18 F6 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:31438 CAPLUS
DOCUMENT NUMBER: 136:102370
TITLE: Preparation of tetrahydropyridine or piperidine heterocyclic derivatives and their affinity for CRF receptors
INVENTOR(S): Nakazato, Atsuro; Kumagai, Toshihito; Okubo, Taketoshi; Kameo, Kazuya
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002002549 A1 20020110 WO 2001-JP5806 20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2001069437 A5 20020114 AU 2001-69437 20010704
EP 1299378 A1 20030409 EP 2001-947819 20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
BR 2001012166 A 20030902 BR 2001-12166 20010704
JP 2004502685 T2 20040129 JP 2002-507801 20010704
NO 2002006125 A 20030204 NO 2002-6125 20021219
US 2004034061 A1 20040219 US 2003-311277 20030825
PRIORITY APPLN. INFO.: JP 2000-204021 A 20000705
JP 2000-270535 A 20000906
WO 2001-JP5806 W 20010704
OTHER SOURCE(S): MARPAT 136:102370

AB Tetrahydropyridine or piperidine heterocyclic derivs. with high affinity for CRF receptors were prepared E.g., 5-(4-carbamoyl-1,2,3,6-tetrahydropyridin-1-yl)-2-(N-ethyl-2,4-dichloroanilino)-4-methylthiazole was prepared by bromination of 2-(N-ethyl-2,4-dichloroanilino)-4-methylthiazole hydrochloride, followed by reaction with 5-carbamoyl-1,2,3,6-tetrahydropyridine hydrochloride.

IT **388122-48-3P 388122-49-4P 388122-50-7P**
388122-52-9P 388122-53-0P 388122-54-1P
388122-55-2P 388122-56-3P 388122-57-4P
388122-58-5P 388122-59-6P 388122-60-9P
388122-61-0P 388122-62-1P 388122-63-2P
388122-64-3P 388122-65-4P 388122-67-6P
388122-68-7P 388122-69-8P 388122-70-1P
388122-71-2P 388122-72-3P 388122-73-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydropyridine or piperidine heterocyclic derivs. and their affinity for CRF receptors)

RN 388122-48-3 CAPLUS

CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-49-4 CAPLUS
CN 4-Pyridinecarboxamide, 1,2,3,6-tetrahydro-1-[2-methyl-8-(2,4,6-trimethylphenyl)-4-quinolinyl]- (9CI) (CA INDEX NAME)



RN 388122-50-7 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dimethoxyphenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-52-9 CAPLUS
CN 4-Pyridineacetamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-53-0 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-[2-chloro-4-(trifluoromethyl)phenyl]-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-54-1 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-[2-chloro-4-(trifluoromethoxy)phenyl]-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-55-2 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,6-dimethoxy-3-pyridinyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-56-3 CAPLUS
CN 4-Pyridinecarboxamide, 1-[6-chloro-8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-57-4 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2,6-dimethyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-58-5 CAPLUS
CN 4-Pyridinecarboxylic acid, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-59-6 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-6-fluoro-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-60-9 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-6-(trifluoromethoxy)-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-61-0 CAPLUS
CN 4-Pyridinecarboxylic acid, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 388122-62-1 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-63-2 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-[2,6-dimethyl-4-(trifluoromethyl)phenyl]-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-64-3 CAPLUS
CN 3-Pyridinecarboxamide, 1,2,5,6-tetrahydro-1-[2-methyl-8-[4-(trifluoromethyl)phenyl]-4-quinolinyl]- (9CI) (CA INDEX NAME)



RN 388122-65-4 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dimethoxyphenyl)-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-67-6 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-6-fluoro-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-68-7 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-6-(trifluoromethoxy)-4-quinolinyl]-1,2,5,6-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 388122-69-8 CAPLUS
CN Acetamide, 2-[1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-4-piperidinylidene]- (9CI) (CA INDEX NAME)



RN 388122-70-1 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-6-(dimethylamino)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-71-2 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-6-(dimethylamino)-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 388122-72-3 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-5-fluoro-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-73-4 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-5-fluoro-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



IT **388123-50-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tetrahydropyridine or piperidine heterocyclic derivs. and their affinity for CRF receptors)
RN 388123-50-0 CAPLUS
CN 1,4-Dioxa-8-azaspiro[4.5]decane, 8-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]- (9CI) (CA INDEX NAME)



IT **388123-52-2P 388123-59-9P 388123-60-2P**
388123-61-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydropyridine or piperidine heterocyclic derivs. and their affinity for CRF receptors)

RN 388123-52-2 CAPLUS
CN 4-Pyridinecarbonitrile, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388123-59-9 CAPLUS
CN Acetic acid, [1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-4-piperidinylidene]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388123-60-2 CAPLUS
CN Acetic acid, [1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-4-piperidinylidene]- (9CI) (CA INDEX NAME)



RN 388123-61-3 CAPLUS
CN 4-Pyridineacetic acid, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 08:43:35 ON 09 APR 2004)

FILE 'REGISTRY' ENTERED AT 08:43:43 ON 09 APR 2004
L1 STRUCTURE UPLOADED
L2 137 S L1 FUL

FILE 'CAPLUS' ENTERED AT 08:44:10 ON 09 APR 2004
L3 3 S L2

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.15	170.78
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.08	-2.08

STN INTERNATIONAL LOGOFF AT 08:45:15 ON 09 APR 2004